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Abstract
There is a controversy about the efficacy of hyperbaric oxygen (HBO) therapy for the treatment of autism. This
study systematically reviews the current evidences for treating of autism with HBO therapy. According to PRISMA
guidelines for a systematic review, the databases of MEDLINE/Pubmed, Google Scholar, and Randomised Controlled
Trials in Hyperbaric Medicine were electronically searched. In addition, medical subject heading terms and text
words for hyperbaric oxygen therapy and autism were used. The main inclusion criteria were published studies
which reported the original data from the trials conducted on the patients with autism and assessed outcomes
with a valid and reliable instrument. A quality assessment was also conducted. The electronically search resulted in
18 title of publications. Two studies were randomized, double-blind, controlled-clinical trials. While some
uncontrolled and controlled studies suggested that HBO therapy is effective for the treatment of autism, these
promising effects are not replicated. Therefore, sham-controlled studies with rigorous methodology are required to
be conducted in order to provide scientific evidence-based HBO therapy for autism treatment.
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Introduction
Hyperbaric oxygen therapy (HBO) is suggested for treat-
ing some medical problems, such as air or gas embo-
lism, carbon monoxide poisoning, intracranial abscess,
and radiation injury; however, its mechanism of action
is not clear [1]. It is suggested that HBO increases the
production of reactive oxygen species [2]. Moreover,
HBO is a safe intervention [1] and middle ear barotrau-
mas is one of its common adverse effect [3].
Autism is a complex neuro-developmental disorder
with an increasing prevalence which is characterized by
three main symptoms, including impairments in sociali-
zation and communication, restricted interests, and
repeated behaviors. Meanwhile, there is no curative
treatment for autism. Moreover, there are only two
Food and Drug Administration (FDA) approved medica-
tions, including risperidone and aripiprazole for mana-
ging its symptoms [4]. Therefore, there is an urgent
need to provide alternative therapeutic approaches for
autism. In recent years, HBO is investigated as an alter-
native treatment for autism. Early uncontrolled studies
reported the efficacy of HBO therapy. However, the
results of later controlled-studies are controversial.
There are many reports about the possible role of
neuro-inflammation in autism [5-9]. This neur-inflam-
mation can be a possible target for the treatment of
some cases with autism [10,11]. Besides, the regional
cerebral blood flow is decreased in the bilateral frontal
lobe, temporal, limbic system, and basal ganglias in aut-
ism spectrum disorders [12]. Moreover, it is proposed
that HBO may improve the cerebral hypoperfusion and
decrease brain inflammation as well as oxidative stress
in autism [13,14]. On the contrary to some expectations,
HBO therapy does not exacerbate the increased oxida-
tive stress in autism [6,15]. Moreover, it does not affect
plasma oxidized glutathione level. However, HBO ther-
apy decreased C-reactive protein (CRP) level in a fasting
blood sample [15]. Also, plasma concentration of some
interleukins (IL), such as IL-1b,I L - 1 R A ,I L - 5 ,I L - 8 ,I L -
12(p70), IL-13, and IL-17 in the children with autism
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[16]. Nevertheless, HBO therapy did not affect the level
of cytokines [17].
The present study is a systematic review of the current
literature regarding the efficacy of HBO therapy for
treating children with autism. There are two objectives:
1) assessment of the effects of HBO therapy for the
treatment of autism, and 2) reporting adverse effects of
HBO therapy in these children and adolescents.
Method
Literature search
This descriptive systematic review was conducted using
the PRISMA (Preferred Reporting Items for Systematic
reviews and Meta-Analyses) guidelines for searching the
literature and reporting the results [18]. The author
reviewed the titles and abstracts of the retrieved articles
in order to assess if they met the established inclusion
criteria.
Types of studies: The current study aimed to review
all non-randomized and randomized clinical trials con-
cerning the use of HBO for the treatment of autism
symptoms. MEDLINE/Pubmed, Google Scholar, and the
Database of Randomised Controlled Trials in Hyperbaric
Medicine (DORCTIHM), which is a specifically targeted
database of clinical evidence in the field of HBO http://
www.hboevidence.com, were electronically searched. In
addition, medical subject heading terms and text words
for ‘hyperbaric oxygen therapy’ AND ‘autism’;a sw e l la s
‘hyperbaric oxygen therapy’ and ‘pervasive developmen-
tal disorder’ were used. These databases were searched
from their starting date to January 2012. Moreover, the
references of all the included papers were searched..
Language was not considered as an exclusion criterion.
The Diagnostic and Statistical Manual of Mental Disor-
ders, 4th Edition, Text Revision, (DSM-IV-TR) was con-
sidered for autism diagnosis.
Types of participants
Participants of any age from both genders with autism
spectrum disorders were included in the present study.
Types of interventions
Trials comparing the beneficial and harmful effects of
HBO therapy with or without adjuvant pharmacotherapy
were included. HBO protocol type was not considered
as an exclusion criterion.
Types of outcome measures
The primary outcome measures assessed the outcomes
with a valid and reliable instrument. Besides, the sec-
ondary outcome measures evaluated any reported
adverse events of HBO therapy.
Data extraction and validity scoring
Both the titles and the abstracts were evaluated for
inclusion based on the participants, the design of trial,
intervention, and outcomes assessment. The articles
which did not meet the inclusion criteria were excluded
from the study. A summary of the flow of information
is displayed in Figure 1. The modified four-item Oxford
scale, whose score ranges from 0 to 7, (cited by [19,20])
was used in order to assess the methodological validity
of the articles (Table 1). Also the information about the
specific diagnosis, HBO therapy and its duration and
protocols, autism symptoms as outcome, and secondary
outcomes (adverse effects) were collected.
Results
Trial flow
In this study, a total of thirty six abstracts were identi-
fied. The initial review of the records showed that 18
articles were duplicated and three ones were irrelevant
(Figure 1). Also, 15 full text articles were retrieved for
additional information. Nevertheless, no unpublished
data were retrieved, and no animal studies were found.
It must be noted that all the retrieved papers were in
English.
Only 2 studies were randomized, double-blind, con-
trolled-clinical trials [21,22]. The retrieved published
documents (articles) included a hypothesis [13], 3 case
series [14,24,25], and 3 commentaries [26-28]. In addi-
tion, 3 articles were not clinical trials [29-31], and 3 stu-
dies were open labeled without any control groups
[15,17,23].
Primary outcome - efficacy
Overall, two published trials including a total of 89 par-
ticipants met the inclusion criteria (Table 2). These two
articles were a high quality. Moreover, both studies
delivered HBO therapy at 24% oxygen and 1.3 atmo-
spheric pressure to the treatment groups [21,22].
In one of these studies conducted by Granpeesheh et
al., both groups received eighty 1-hour sessions of HBO
therapy (Table 2). The HBO therapy group received the
compression to 1.3 atmospheric pressure with a supple-
mental oxygen (approximately 24-28% FiO2), while the
control group received free airflow through the chamber
at ambient pressure [21]. This study included the chil-
dren aging from 2 to 14 who suffered from autistic dis-
order. In addition, participants could take any
supplements, pharmacological interventions, and dietary
modifications. Moreover, Applied Behavior Analysis
(ABA) was administered for many patients in both
groups. However, these interventions were constant dur-
ing the study. Nevertheless, medical conditions, such as
seizures, chronic or current sinus infections, or current
otitis media, were considered as the exclusion criteria.
Overall, twelve out of the 46 patients withdrew from
the trial. Therefore, only 16 patients in control group
and 18 patients in the treatment group completed the
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Additional records identified 
through other sources  
(n =0) 
Records after duplicates removed  
(n = 18) 
Records screened  
(n =18) 
Records excluded  
(n = 3) 
Full-text articles assessed 
for eligibility  
(n =15) 
Full-text articles excluded, 
with reasons:  
Not a clinical trial (n=3)
Hypothesis (n=1)
Case series (n=3)
Commentary (n=3)
Open labelled without 
control group (n=3)
Studies included in 
qualitative synthesis  
(n = 2) 
Figure 1 Flowchart of PRISMA trial selection process.
Table 1 Validity scoring of the trials
Study Randomization(0
to 2)
Concealment of allocation (0
to 1)
Double-blinding(0
to 2)
complete reporting of data(0
to 2)
Total validity
scoring
Granpeesheh
[21]
21 2 1 6
Rossignol [22] 2 1 2 1.5 6.5
Rossignol [15] 00 0 2 2
Jepson [23] 00 0 2 2
Bent [17] 00 0 2 2
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due to the adverse effect; the patient had experienced
seizure [21].
In addition to the direct observation, a large variety of
assessments, such as the Aberrant Behavior Checklist
[32], the Autism Diagnostic Observation Schedule-Gen-
eric (ADOS) [33], Behavior Rating Inventory of Execu-
tive Functioning [34], and Clinical Global Impression
Scale (CGI), were administered, as well. The authors
used intent-to-treat analyses to examine the results.
However, only 34 out of 46 patients were included for
data analysis. In fact, 12 patients who were excluded
from the study were not included in the statistical
analysis.
The primary outcome measures of social reciprocity,
communicative approach, and repetitive behaviors were
not different between the two groups after the interven-
tions. Subtracting the pret-test and post-test scores of
each subscales of the Social Responsiveness Scale (SRS)
showed that the mean differences were not different
between the two groups. In addition, the number of the
patients in the two groups was not statistically different
regarding the improved communication (3 versus 2) as
well as socialization (3 versus 2) and the total score of
ADOS (5 versus 4). Also, the results of the direct obser-
vation did not support the idea that HBO therapy was
more effective than free airflow through the chamber at
ambient pressure [21]. Overall, the authors concluded
that HBO therapy with 24% oxygen at 1.3 atm did not
treat the children with autism [21].
Another study, which was conducted by Rossignol et
al., was a multicenter, randomized, double-blind, con-
trolled trial including 62 children from 2 to 7 years old
suffering from autism and had been randomly allocated
in two groups [22]. Hyperbaric treatment group received
40 1-hour treatments of hyperbaric treatment at 1.3
atmosphere (atm) and 24% oxygen. The control group,
on the other hand, receiveds l i g h t l yp r e s s u r i z e dr o o m
air at 1.03 atm and 21% oxygen. Seven patients (4
patients in the HBO therapy group and 3 patients in the
control group) dropped from this study. Intent-to-treat
analysis was used for statistical analysis and all the parti-
cipants were included in the analysis [22]. The authors
reported that HBO therapy improved the overall func-
tioning (p = 0.0008), receptive language (p < 0.0001),
social interaction (p = 0.0473), and eye contact (p =
0.0102). In addition, the total score of ABC and its sub-
scale of irritability in the HBO therapy group were
improved more than those of the control group [22].
Nonrandomized studies
Bent et al. reported that HBO was effective for the treat-
ment of autism, while it did not affect the cytokines
level [17]. It needs to be noticed that none of the
patients in that study had an abnormal level of cytokines
at the beginning of the study [17]. As the authors men-
tioned, their study was an open-label one (Table 3). So,
there is a speculation that this effect may be due to the
placebo effects. Some symptoms may change in the clin-
ical course of autism. Moreover, their participants were
Table 2 Summary of included studies
References Methods Participants Interventions Measurements Outcome and adverse effects
[21] Multicenter,
randomized,
double-blind,
controlled
trial.
62 children with autism,
ages 2-7 years old (mean
4.92 +/- 1.21), control
group (n = 29) treatment
group (n = 33)
40 hourly treatments. treatment
group: hyperbaric treatment at 1.3
atmosphere (atm) and 24% oxygen,
control group: slightly pressurized
room air at 1.03 atm and 21%
oxygen
Clinical Global
Impression
(CGI) scale,
Aberrant
Behavior
Checklist (ABC)
Autism
Treatment
Evaluation
Checklist
(ATEC).
Improvement according to: mean
CGI scores (p = 0.0008), receptive
language (p < 0.0001), social
interaction (p = 0.0473), and eye
contact (p = 0.0102);
ABC total score: no improvement
except a greater number of
children improved in irritability (p
= 0.0311).
ATEC: sensory/cognitive awareness
improved (p = 0.0367)
HBO: safe and well-tolerated.
[22] Randomized,
double-blind,
placebo-
controlled
design
Children aged 2 to 14
(mean age = 6.18).
46 children enrolled in the
study, 12 children
withdrew, placebo group(n
= 16 treatment group(n =
180
80 hourly sessions for both groups
HBO group: 1.3 atm and
supplemental oxygen
(approximately 24-28% FiO2)
placebo group: free airflow through
the chamber at ambient pressure
supplements, dietary modifications,
and medical interventions were
held constant during the
intervention [mean number of
Applied Behavior Analysis (ABA)
treatment hours per month was
109 (HBO 114.7; placebo 103.3)]
Aberrant
Behavior
Checklist (ABC)
Autism
Diagnostic
Observation
Schedule-
Generic (ADOS)
Clinical Global
Impression
Scale (CGI)
Direct
observations
HOT is not more effective than
placebo.
1 withdrew after a seizure attack.
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autism. Therefore, it cannot be guaranteed that the
improvement is induced by the intervention or other
effects. In addition, the parental bias in reporting the
symptoms in an open label study needs to be consid-
ered, as well. Of course, the improvement measured by
CGI was also reported by the study. Therefore, this dif-
ference cannot be explained by parental reporting bias.
Another study which reported the efficacy of 40
hyperbaric sessions lasting for 45 minutes on autism
was an open-label study [15]. According to the results,
HBO therapy increased motivation, speech, and cogni-
tive awareness. Moreover, there were no major adverse
effects [15].
A case-series study reported that HBO is effective for
treatment of the children with autism [25]. However,
there are some ambiguities about its results; for
instance, it is not clear whether the participants take
any con-current medication. Moreover, they did not
mention how they measured autism symptoms. They
Table 3 Summary of non-randomized trials
References Methods Participants Interventions Measurements Outcome and adverse
effects
[17] Case series 10 children 40 days of HBO (1.5
atmosphere absolute; 100%
oxygen) for 1 h, 5 days a
week for 8 weeks, followed
by a 4 week break, and then
another 40 treatments over 8
weeks
+
Concurrent stable medical
regime
Aberrant Behavior Checklist
(ABC)
Pervasive Developmental
Disorder Behavior Inventory
(PDDBI)
Significant improvements in
total score and 3 of the 5
subscales of the Aberrant
Behavior Checklist (ABC)
including irritability, lethargy,
and hyperactivity
Improvements in 3 out of ten
subscales of Developmental
Disorder Behavior Inventory
(PDDBI)
No effects on cytokines level
Adverse effects: 3 ear
discomfort, 2 ear infections, 1
increased hyperactivity, 1
increased vocal sensitivity, 1
increased sensory needs, 1
insomnia, 1 dehydration, 1
fatigue, 1 irritability, 1
increased mouthing of
objects, and 1 seizure.
[15] An open-
label pilot
study
18 children with
autism, 3 to16 years
old
40 hyperbaric sessions of 45
minutes
1.3 atm and 24% oxygen or
1.5 atm and 100% oxygen
Concurrent medication was
allowed. However, no new
medication was administered
during the study.
Childhood Autism Rating
Scale (CARS)
Significant improvements for
motivation, speech, and
cognitive awareness (p <
0.05).
No major adverse events
[14] Retrospective
study
6 children with autism 40 sessions of one hour of
HBO at 1.3 ATA an 28-30%
oxygen + concurrent
therapies
Autism Treatment Evaluation
Checklist (ATEC), Childhood
Autism Rating Scale (CARS),
and Social Responsiveness
Scale (SRS)
Decreased symptoms, well
tolerated
[23] Case series 7 children HBO (1.3 Atmospheric
pressure., 100% oxygen, 10
sessions) treatment
Used instrument is not
mentioned
Improvement No serious
adverse effect
[31] Case series
study
16 children with mean
age of 5 years and 9
months (range = 3
years and 10 months-9
years and 5 months).
40 sessions of HBO (24%
oxygen and 1.3 ATA) on 11
topographies of directly
observed
Behavior
No change in medical
treatment regimen or dietary
regimen for 6 weeks prior to
the study.
Direct observation Play
sessions
(a) vocal initiations behavior;
(b) physical initiations; (c)
vocal response; (d) physical
response; (e) self-injurious
behavior or aggression; (f)
disruption; (g) tantrums; (h)
vocal stereotypy; and (i)
physical stereotypy
HBO neither improves nor
worsens the autism
symptoms.
[24] Case report Three children 88% (+/- 3%) oxygen at 1.3
ATA
On topographies of behaviors
A Child
Responses Measured was
defined.
Two of the three children had
improvements.
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criteria for the improvement are not described. How-
ever, that study has a strong point, it measured fine
motor, eye-hand coordination, language development,
and gross motor development. These items are more
objective than social or communication problems.
A retrospective case study including 6 patients
reported that HBO is effective. The average improve-
ment in parent-reported Autism Treatment Evaluation
Checklist (ATEC) ranged from 8.8% to 31.6% in older
children and younger children, respectively. The results
of the statistical analysis showed P value to be 0.0538
which is a trend for statistical significancy [14]. In addi-
tion, the average improvement on Childhood Autism
Rating Scale (CARS) was 12.1% (P = 0.0178). Besides,
the average score on Social Responsiveness Scale (SRS)
was 22.1% with aP value of 0.0518 which again, shows a
trend for a statistically significant difference. These
results suggest promising effects. However, it is needed
to be confirmed in further studies because these patients
were allowed to take concomitant therapies and, at the
same time, new therapies were allowed to be added dur-
ing this retrospective case study [14].
HBO therapy related adverse effects
In a study conducted by Granpeesheh et al., no baro-
trauma related adverse effects (such as pressure injury
to tympanic membranes, and sinuses) were reported.
Nevertheless, no adverse effect were reported for HBO
therapy [21]. The other randomized controlled study
also reported the HBO-related adverse effects including
urinary frequency (1 case) and skin rash (1 case). Also,
asthma symptoms were exacerbated in one patient in
the treatment group (Table 2) [22].
Discussion
There is only one controlled study supporting the effi-
cacy of HBO therapy for autism. However, another ran-
domized, double-blind, controlled trial did not support
the efficacy of HBO therapy for the treatment of autism
[21]. There are several points regarding that study [21].
First, 12 out of the 46 participants withdrew from the
study. Therefore, the number of the patients in each
group was limited; however, it is not clear whether the
negative results can be attributed to the small sample
size. In addition, the control group received free airflow
through the chamber at ambient pressure. It is a debate
whether this is really a placebo intervention. It should
be noted that the participants in both groups showed
improvement over time. Of course, it does not mean
that other options for HBO therapy, such as other
doses, are not effective. Furthermore, both groups were
administered intensive ABA intervention during this
study. One explanation for the lack of efficacy is that
HBO therapy does not add significant therapeutic effects
to ABA; therefore, It cannot be interpreted that HBO
therapy is ineffective. However, it is not clear if direct
observation has enough reliability and validity to be con-
sidered as an outcome measure.
The other randomized, double-blind, placebo-con-
trolled trial reported that some children with autism can
benefit from HBO therapy [22]. However, there are
some concerns about that study. The measures used in
that study were Clinical Global Impression scale, Aber-
rant Behavior Checklist (ABC), and Autism Treatment
Evaluation Checklist (ATEC). In addition, an intention-
to-treat approach was used for statistical analysis. One
of the measures used in that study was CGI. It is
expected that clinicians rate CGI to show the degree of
changes. Although, CGI is not scored at baseline, both
parents and physician scored CGI at baseline in that
study. Moreover, the improvement of overall function-
ing, receptive language, social interaction, and eye con-
tact were assessed according to CGI. Meanwhile, CGI is
used in order to show the overall changes. Of course,
the validity and reliability of CGI for assessment of over-
all functioning, receptive language, social interaction,
and eye contact in autism should be investigated.
Of course, another scale was also used in that study.
As the results showed, no difference was observed
between the two groups regarding the ABC total score
and subscale scores (p = ns). However, there was a
trend for a significant difference between the two groups
regarding the irritability subscale score (p = 0.0976).
Autism Treatment Evaluation Checklist (ATEC) Scale
was also administered. Sensory/cognitive awareness in
the treatment group improved more than that of control
group. However, 10 patients in the treatment group and
8 patients in the control group were not assessed at
baseline by this scale; therefore, the data for 44 patients
were gathered. Nevertheless, it is not clear whether it
has any impact on the results of this study. In addition,
it is not clear whether the statistical differences are due
to the alpha inflation.
There are some other possible explanations for the
difference between these two studies’ findings. a) The
patients’ diagnostic characteristics of these two trials are
not similar. While one of them included the patients
with autism spectrum disorders [21], the other study
included the patients with autism [22]. In addition, the
children with PDD-NOS, Asperger syndrome, and fra-
g i l eXs y n d r o m ew e r ee x c l u d e df r o mt h es t u d y[ 2 2 ] .b )
One study supported the efficacy of HBO therapy
according to CGI as an outcome measure [22], while
the other study did not find these results using CGI. c)
Only one of these two studies reported that the patients
demographic characteristics (age and gender ratio) and
baseline severity were not different between the
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study included children aged 2 to 14 years old [21], the
other study included those between 2 and 7 years old
[22]. e) One study was a multicenter study [22], while
the other study was conducted in one center [21]. It
needs to be mentioned that the age of the children, aut-
ism severity, and the degree of improvement were not
different between these six centers [22]. f) While the
outcomes were assessed by the parents or primary care-
takers and the treating physician [22], the trained asses-
sors, who were blind to group assignment, and
evaluated the outcome for another trial [22]. g) The
assessment of blinding was conducted for one study
[21], while it was not performed for the other one [21].
h) One study provided about 5 treatments per week
[21], while the other study provided 10 treatments per
week [22].
This systematic review has a limitation because only
one author reviewed the articles and scored the quality
of the experimental studies.
In conclusion, the results supporting the efficacy of
HBO therapy are not replicated. In addition, none of
these trials used placebo group. Therefore, these results
are not conclusive for the efficacy of HBO therapy for
the treatment of autism. However, the promising effects
of case series studies and the only multicenter, rando-
mized, controlled trial encourage conducting further
clinical trials with more rigorous scientific methodolo-
gies. In general, since control group should receive
some pressure to stimulate HBO therapy, it is not prac-
tical to conduct a placebo controlled study for HBO
therapy. Therefore, sham controlled studies are recom-
mended to be conducted. Examining different pressures
and oxygen levels is suggested, as well. Further studies
should consider that more than half of patients with
pervasive developmental disorders suffer from attention
deficit hyperactivity disorder as a co-morbidity [35].
Serious adverse effects are not reported in controlled
studies. However, it does not guarantee that HBO ther-
apy in higher pressures and oxygen levels is safe in aut-
ism. In fact, more studies including larger samples of
patients are needed to be conducted.
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